Euglycem® plus recommended diet to lower blood sugar in people with dysglycemia
Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Euglycem in Reducing Blood Glucose in Patients With Dysglycemia After Three Months of Treatment - EUGLYCARE Study
This will see if taking the supplement Euglycem® alongside a recommended diet lowers fasting blood sugar after three months in adults with dysglycemia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 2 sites (Pavia, Lombardy and 1 other locations) |
| Trial ID | NCT07263789 on ClinicalTrials.gov |
What this trial studies
Adults with dysglycemia and BMI ≤30 will follow a recommended standard diet and receive either Euglycem® or a placebo for three months. The main measure is change in fasting plasma glucose from baseline to three months. Participants taking medications that affect blood glucose or currently enrolled in other investigational drug/device trials are excluded. Study visits take place at the IRCCS Policlinico San Matteo in Pavia, Italy.
Who should consider this trial
Good fit: Adults with dysglycemia (prediabetes), BMI ≤30 kg/m2, able to consent and willing to follow the diet and study visits are the ideal candidates.
Not a fit: People already taking drugs that affect blood glucose, those with BMI >30, or those enrolled in another investigational trial are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could help lower fasting blood sugar and potentially reduce the risk of progressing to type 2 diabetes.
How similar studies have performed: Similar nutraceutical approaches have shown mixed results in small trials, with some modest glucose-lowering effects but overall limited and inconsistent evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI ≤30 kg/m2 * subjects able to understand the informed consent and sign it before enrollment in the study * subjects willing to follow all study requirements and perform all study visits as well as collaborate with the investigator. Exclusion Criteria: * ongoing treatment with drugs that can affect blood glucose * current participation in another investigational drug or investigational device trial or inclusion in another investigational drug or investigational device trial within the previous month
Where this trial is running
Pavia, Lombardy and 1 other locations
- IRCCS Policlinico San Matteo — Pavia, Lombardy, Italy (Recruiting)
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Pavia, Italy (Not_yet_recruiting)
Study contacts
- Study coordinator: Giuseppe Derosa, MD
- Email: g.derosa@smatteo.pv.it
- Phone: +390382502614
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.